Literature DB >> 11988846

Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.

Michael Kragh1, Bjørn Quistorff, Michael R Horsman, Paul E G Kristjansen.   

Abstract

The potential of noninvasive laser Doppler flowmetry (LDF) and near infrared spectroscopy (NIRS) to detect acute effects of different vascular-modifying agents on perfusion and blood volume in tumors was evaluated. C3H mouse mammary carcinomas (approximately 200 mm(3)) in the rear foot of CDF1 mice were treated with flavone acetic acid (FAA, 150 mg/kg), 5,6-dimethylxanthenone-4-acetic acid (DMXAA, 20 mg/kg), combretastatin A-4 disodium phosphate (CA4DP, 250 mg/kg), hydralazine (HDZ, 5 mg/kg), or nicotinamide (NTA, 500 mg/kg). Tumor perfusion before and after treatment was evaluated by noninvasive LDF, using a 41 degrees C heated custom-built LDF probe with four integrated laser/receiver units, and tumor blood volume was estimated by NIRS, using light guide coupled reflectance measurements at 800+/-10 nm. FAA, DMXAA, CA4DP, and HDZ significantly decreased tumor perfusion by 50%, 47%, 73%, and 78%, respectively. In addition, FAA, DMXAA, and HDZ significantly reduced the blood volume within the tumor, indicating that these compounds to some degree shunted blood from the tumor to adjacent tissue, HDZ being most potent. CA4DP caused no change in the tumor blood volume, indicating that the mechanism of action of CA4DP was vascular shut down with the blood pool trapped in the tumor. NTA caused no change in either tumor perfusion or tumor blood volume. We conclude that noninvasive LDF and NIRS can determine acute effects of vascular modifying agents on tumor perfusion and blood volume.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988846      PMCID: PMC1531700          DOI: 10.1038/sj.neo.7900230

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  38 in total

1.  Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.

Authors:  D J Chaplin; G R Pettit; S A Hill
Journal:  Anticancer Res       Date:  1999 Jan-Feb       Impact factor: 2.480

2.  In vivo evaluation of microcirculation by coherent light scattering.

Authors:  M D Stern
Journal:  Nature       Date:  1975-03-06       Impact factor: 49.962

3.  Quantitative estimates of angiogenic and anti-angiogenic activity by laser Doppler flowmetry (LDF) and near infra-red spectroscopy (NIRS).

Authors:  M Kragh; B Quistorff; P E Kristjansen
Journal:  Eur J Cancer       Date:  2001-05       Impact factor: 9.162

4.  Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

Authors:  R Murata; J Overgaard; M R Horsman
Journal:  Int J Radiat Biol       Date:  2001-02       Impact factor: 2.694

5.  Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.

Authors:  C Malcontenti-Wilson; V Muralidharan; S Skinner; C Christophi; D Sherris; P E O'Brien
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

6.  Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.

Authors:  S M Galbraith; D J Chaplin; F Lee; M R Stratford; R J Locke; B Vojnovic; G M Tozer
Journal:  Anticancer Res       Date:  2001 Jan-Feb       Impact factor: 2.480

7.  Non-invasive tumour blood perfusion measurement by 2H magnetic resonance.

Authors:  L Bentzen; M R Horsman; P Daugaard; R J Maxwell
Journal:  NMR Biomed       Date:  2000-12       Impact factor: 4.044

8.  Quantitative estimates of vascularity in solid tumors by non-invasive near-infrared spectroscopy.

Authors:  M Kragh; B Quistorff; E L Lund; P E Kristjansen
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

9.  Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.

Authors:  L M Ching; D Goldsmith; W R Joseph; H Körner; J D Sedgwick; B C Baguley
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

10.  In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.

Authors:  K Grosios; S E Holwell; A T McGown; G R Pettit; M C Bibby
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  4 in total

1.  In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.

Authors:  Dawen Zhao; Cheng-Hui Chang; Jae G Kim; Hanli Liu; Ralph P Mason
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-23       Impact factor: 7.038

2.  Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.

Authors:  Carsten D Ley; Michael R Horsman; Paul E G Kristjansen
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

3.  Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI.

Authors:  Dawen Zhao; Edmond Richer; Peter P Antich; Ralph P Mason
Journal:  FASEB J       Date:  2008-02-08       Impact factor: 5.191

4.  Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.

Authors:  Meng Gao; Dongjian Zhang; Qiaomei Jin; Cuihua Jiang; Cong Wang; Jindian Li; Fei Peng; Dejian Huang; Jian Zhang; Shaoli Song
Journal:  Oncotarget       Date:  2016-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.